Stocktoria
Lexeo Therapeutics, Inc. LXEO
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2023-11-03
Chart by TradingView
3/9
Piotroski F — financial health
8.61
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Financials | ||||
| Revenue | — | — | — | $654,000 |
| Operating income | -$109.3M | -$105.8M | -$68.5M | -$60.5M |
| Net income | -$100.0M | -$98.3M | -$66.4M | -$59.3M |
| Operating cash flow | -$98.6M | -$81.2M | -$59.5M | -$54.6M |
| Free cash flow | -$99.0M | -$81.6M | -$59.6M | -$55.2M |
| Total assets | $268.7M | $146.9M | $139.8M | $97.1M |
| Total liabilities | $22.0M | $30.1M | $26.3M | $25.0M |
| Shareholders' equity | $246.7M | $116.8M | $113.5M | -$113.0M |
| Ratios | ||||
| Operating margin | — | — | — | -9252.1% |
| Net margin | — | — | — | -9063.8% |
| FCF margin | — | — | — | -8445.3% |
| Return on assets | -37.2% | -66.9% | -47.5% | -61.1% |
| Return on equity | -40.5% | -84.2% | -58.5% | 52.5% |
| Current ratio | 11.21 | 5.52 | 7.21 | 5.58 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| Point72 Asset Management, L.P. | 1,680,449 | $9.6M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 8.61 (safe)
- Working capital / assets 0.639
- Retained earnings / assets -1.415
- EBIT / assets -0.407
- Equity / liabilities 11.203
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001907108 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.